Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership $6.49 +0.23 (+3.67%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.51 +0.02 (+0.31%) As of 07/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.43%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$1.60M Get RXRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Recursion Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address RXRX Insider Buying and Selling by Quarter Recursion Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/13/2024Michael SecoraCFOSell15,000$7.66$114,900.00 11/12/2024Blake BorgesonDirectorSell11,447$7.64$87,455.08 10/29/2024Blake BorgesonDirectorSell11,447$6.72$76,923.84 10/24/2024Tina MarriottCOOSell6,000$6.31$37,860.00 10/15/2024Blake BorgesonDirectorSell11,447$6.67$76,351.49 10/8/2024Michael SecoraCFOSell15,000$6.32$94,800.00 10/2/2024Christopher GibsonCEOSell20,000$6.16$123,200.00 10/1/2024Blake BorgesonDirectorSell11,447$6.22$71,200.34 9/26/2024Tina MarriottCOOSell6,000$7.00$42,000.00 9/17/2024Blake BorgesonDirectorSell11,447$6.84$78,297.48 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/10/2024Michael SecoraCFOSell15,000$6.17$92,550.00 9/4/2024Christopher GibsonCEOSell20,000$6.04$120,800.00 9/3/2024Blake BorgesonDirectorSell11,447$6.27$71,772.69 8/29/2024Tina MarriottCOOSell6,000$7.56$45,360.00 8/20/2024Blake BorgesonDirectorSell11,447$7.12$81,502.64 8/13/2024Michael SecoraCFOSell15,000$6.35$95,250.00 8/7/2024Christopher GibsonCEOSell30,000$7.10$213,000.00 8/6/2024Blake BorgesonDirectorSell11,447$6.82$78,068.54 (Data available from 1/1/2013 forward) RXRX Insider Trading Activity - Frequently Asked Questions Who is on Recursion Pharmaceuticals' Insider Roster? The list of insiders at Recursion Pharmaceuticals includes Blake Borgeson, Christopher Gibson, Dean Y Li, Michael Secora, Mubadala Investment Co Pjsc, Shafique Virani, Terry-Ann Burrell, Tina Marriott, Tina Marriott Larson, and Zavain Dar. Learn more on insiders at RXRX. What percentage of Recursion Pharmaceuticals stock is owned by insiders? 8.43% of Recursion Pharmaceuticals stock is owned by insiders. Learn more on RXRX's insider holdings. Which Recursion Pharmaceuticals insiders have been selling company stock? The following insiders have sold RXRX shares in the last 24 months: Blake Borgeson ($3,447,443.68), Christopher Gibson ($5,781,512.80), Dean Y Li ($396,140.00), Michael Secora ($2,565,129.92), Shafique Virani ($1,210,700.00), Tina Marriott ($471,730.00), Tina Marriott Larson ($278,070.00), and Zavain Dar ($181,269.00). How much insider selling is happening at Recursion Pharmaceuticals? Insiders have sold a total of 1,639,017 Recursion Pharmaceuticals shares in the last 24 months for a total of $14,331,995.40 sold. Recursion Pharmaceuticals Key ExecutivesDr. Christopher C. Gibson Ph.D. (Age 41)Co-Founder, CEO & Director Compensation: $806.72kMs. Tina Marriott Larson (Age 49)COO & President Compensation: $702.24kDr. Blake C. Borgeson Ph.D. (Age 42)Co-Founder & Director Compensation: $40kDr. Michael Secora Ph.D. (Age 41)Chief Financial Officer Compensation: $629.78kDr. David J. Mauro M.D. (Age 59)Ph.D., Chief Medical Officer Compensation: $674.74kKevin LeggatVice President of Finance & AccountingMr. Benjamin Mabey M.S. (Age 41)Chief Technology Officer Mr. Jared AllenbachSenior Director of Investor RelationsMr. Nathan HatfieldChief Legal Officer & General CounselMr. Ryan KellyChief Communications Officer More Insider Trading Tools from MarketBeat Related Companies Viatris Insider Buying Verona Pharma PLC American Depositary Share Insider Buying BridgeBio Pharma Insider Buying Blueprint Medicines Insider Buying Roivant Sciences Insider Buying Elanco Animal Health Insider Buying Revolution Medicines Insider Buying Grifols Insider Buying TG Therapeutics Insider Buying Nuvalent Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional Support This page (NASDAQ:RXRX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
